Cancer-free for 18 years: CAR-T therapy sets new milestone in neuroblastoma treatment

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children with neuroblastoma, with one patient remaining cancer-free for over 18 years.

Opinion | ‘We Lost Our Community, We Lost Our Neighborhood’: What We Heard This Week

“Not only did we lose our home. We lost our community, we lost our neighborhood.” — Sion Roy, MD, of Harbor UCLA Medical Center, on

January 20, 2025

Cambrex sells drug product business; Landmark to work with Galapagos; Genezen locks $18.5M equity boost

Welcome to Endpoints News’ manufacturing news briefs, where we bring you essential updates on new builds, collaborations, recalls and more. CDMO Cambrex sold its drug

November 10, 2023

Clinical Challenges: What Physicians Prescribe Affects Dry Eye Disease

It takes a village of physicians to limit the effects of dry eye disease (DED). Primary care physicians are often the first points of contact

November 17, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.